TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in knee range of motion by universal goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain by 'Numeric Pain Rating Scale'
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in strength by Sphygmomanometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk rates of adverse events of high clinical interest
Endpoint domain: Adverse events/effects
Primary endpoint: Risk rates of common complications of breast surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory testing (haematology and biochemistry panel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reticulocyte percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Homeostatic markers of iron metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP) in the Left Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in End-expiratory Lung Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forms of Self-Criticizing/Attacking and Self-Reassurance Scale (FSCRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire-4 (PHQ-4)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Compassion Scale - Short Form (SCS-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant Feedback Questionnaire (PFQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Febuxostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Morphine Milligram Equivalents Use (MME)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Internal jugular vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IMC thickness assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HgA1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participants' satisfaction about the training course
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' knowledge about scientific writing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Students' skills in scientific writing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: overall flap survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Short term disease remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid term remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brown adipose tissue activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of Carfilzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in dental pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Cavernosal Nerve Stimulation Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GSK-3 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade and frequency of toxicities including cytokine release syndrome (CRS) and neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of transduced T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose metabolism assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CPV-measured pre-/post-difference in quality score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CPV-measured differences in evidence-based decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during intramuscular delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort level during intramuscular delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of morphine for PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conversion rate to complete resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: prevalence of thyroid dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intestinal microbiome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Auditory Discrimination Task: Interstimulus Interval (ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive inhibition deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee Injury and Osteoarthritis Outcomes Survey (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of periorbital hyperpigmentation through photo evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of periorbital hyperpigmentation through dermoscopy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the patient satisfaction evaluation: scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentrations of short chain fatty acids (SCFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: First Major Adverse Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in 12-lead electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Anxiety-1 levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety-2 levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: usage of volatile anesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of therapeutic molecular targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Groin Wound Complication
Endpoint domain: Adverse events/effects
Primary endpoint: frequency and nature of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: nature, severity, and relatedness of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: changes in vital signs and clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in TB Bacterial Load in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Care recipient nursing home/institutional placement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Caregiver emotional stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability index (ODI) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discharge Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Persistent Organ Dysfunction (POD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in laboratory levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the liver and spleen size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of reminder after 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of AZD5985
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Ovary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Spinal posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined mortality and MACE rate
Endpoint domain: Mortality/survival
Primary endpoint: Graft take rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal values for laryngopharyngeal reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substrate metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alpha-Glutathione-S-Transferase (alpha GST) prediction of advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MARINA Index prediction of advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Caregivers Who Agree to Participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Eligible Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Retention of Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UTI Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Steady State Concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI brain activity (BOLD signal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Roland-Morris Disability Questionnaire score at five weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Tissue temperature at five weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of Nilotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Nilotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SSRI/SNRI blood levels after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in BDI (Beck Depression Inventory) II questionnaire scores after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence Rate of Serious Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Markers of Immune Senescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with sustained antiviral activity effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in functional exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to cardiac rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of patients that complete study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of serious adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Capsule Aspect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Activity Log - 14, Amount of Use sub scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recto-anal angle in relax position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recto-anal angle in retain position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recto-anal angle in push position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic MRI: anterior compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic MRI: medium compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiotherapy-associated toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Standard deviation of SEpostop-SEpredicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' discomfort scale after endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum safe dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ICU and hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients With Successful Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Change From Baseline in QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical implantation per transferred embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: level of COMFORT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tissue Flap Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of healing of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Late effects of radiation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Responses in Nasal Secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incisor alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lanugo hair presence/absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of viable pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: anticipated and actual discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Monocyte subset and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NK cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating relative and absolute counts of T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: occurrence of sustained supra-ventricular arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of polyps or lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of CD34+ stem cell selection
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of IMA950
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Breakthrough Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Total acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolapse Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of retinal capillary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neural activity in response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peripheral acute stress reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: disease response after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Depression Measures at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operation-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pool Corrected Signal Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of Detected LGE Signal Correlate to the Respiratory Navigator Scheme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of BKV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Soft tissue evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Increase in ALSFRS-R Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcomes of all cause death, myocardial infarction, stroke, and any revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Peritoneal carcinomatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: improvement of hypotension and hematology profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of erythropoietin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of plasma carnitine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of HLA-B*5701
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Emergency Department Visits and Inpatient Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success Rate of Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of near to complete reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range-of-motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narcotics usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease Activity Score Based on 28-Joint Count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: survival without infection
Endpoint domain: Mortality/survival
Primary endpoint: Continuous measurement of energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the number of major amputations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in in-hospital and long-term mortality rates
Endpoint domain: Mortality/survival